Medical Design Sourcing

Know Labs

Study supports feasibility of Know Labs non-invasive CGM

[Image from Know Labs]Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM.

The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle.

Know Labs conducted a series of internal studies between December 2022 and February 2023. The company sought to validate the technical feasibility of its Bio-RFID sensor technology for quantifying blood glucose concentration (BGC). Its studies evaluated five healthy participants using the Dexcom G6 as a reference device.

Get the full story at our sister site, Drug Delivery Business News.

Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring

[Image from Know Labs]Know Labs (NYSE:KNW) announced today that it established a scientific advisory board to accelerate development for its glucose monitoring devices.

Seattle-based Know Labs expects the members to advise on algorithm refinement, device development, clinical trial design and research publication strategy. They’ll work alongside the company’s current medical and regulatory advisory board members.

The company develops its proprietary Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first application of Bio-RFID as a non-invasive glucose monitor.

Get the full story at our sister site, Drug Delivery Business News.

Know Labs inks partnerships to accelerate progress toward FDA clearance for glucose monitor

[Image from Know Labs]Know Labs (NYSE:KNW) announced that it entered into a series of strategic partnerships as it looks to move toward a major regulatory nod.

Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first application of Bio-RFID as a non-invasive glucose monitor.

Get the full story at our sister site, Drug Delivery Business News.

Glucose monitor maker Know Labs names new CEO, makes other executive changes

[Image from Know Labs]Know Labs (NYSE:KNW) announced that it named Ron Erickson as CEO as the company makes a handful of changes at the top.

The Seattle-based non-invasive glucose monitor maker’s board unanimously named Erickson, its founder and chair, as CEO. Former CEO Phil Bosua stepped down as an executive officer of the company and board member. Know Labs said Bosua will become a technology advisor and consultant to the company, effective immediately.

Get the full story at our sister site, Drug Delivery Business News.

Know Labs wins new glucose monitoring patent

[Image from Know Labs]Know Labs (NYSE:KNW) announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard.

Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. The first application of the technology comes in the form of a non-invasive glucose monitor.

The company’s new patent equates the technology to mean absolute relative difference, or MARD. This standard, used by diabetes researchers and glucose meter makers, establishes a range of clinical accuracy. Know Labs said the patent expands its IP portfolio to nearly 90 patents issued and pending.

Get the full story at our sister site, Drug Delivery Business News.

Glucose monitor maker Know Labs expands leadership team

[Image from Know Labs]Non-invasive glucose monitor developer Know Labs (OTCQB:KNWN) announced today that it added two executives to its leadership team.

Seattle-based Know Labs — which aims to make the first non-invasive glucose monitor cleared by the FDA — added Steven Kent as its new chief product officer, along with Peter Conley as its CFO and SVP of intellectual property.

Get the full story at our sister site, Drug Delivery Business News.

Know Labs signs research agreement with Mayo Clinic

Know Labs today said it entered a research agreement with the Mayo Clinic to test and validate its Bio-RFID as a continuous glucose monitor.

Know Labs’ Bio-RFID technology is designed to be integrated in a number of wearable, mobile or bench-top form factors.

“We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBand CGM,” Know Labs CEO Phil Bosua said in a news release.

Know Labs plans to launch its Bio-RFID within its wearable UBand as a non-invasive continuous glucose monitor.